The distinct catalytic site responsible for the neomorphic activity of mutant-IDH coupled with the evidence that mutant-IDH is important for AML pathogenesis, prompted rapid drug discovery to target mutant-IDH. The gene discussed is IDH2; the disease is acute myeloid leukemia.